.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Queensland Health
Chinese Patent Office
Harvard Business School
Federal Trade Commission
US Department of Justice
Boehringer Ingelheim
Mallinckrodt
Cerilliant
Fish and Richardson

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022529

« Back to Dashboard
NDA 022529 describes BELVIQ, which is a drug marketed by Eisai Inc and is included in two NDAs. It is available from one supplier. There are sixteen patents protecting this drug and two Paragraph IV challenges. Additional details are available on the BELVIQ profile page.

The generic ingredient in BELVIQ is lorcaserin hydrochloride. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lorcaserin hydrochloride profile page.

Summary for 022529

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:16
Formulation / Manufacturing:see details

Pharmacology for NDA: 022529

Suppliers and Packaging for NDA: 022529

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BELVIQ
lorcaserin hydrochloride
TABLET;ORAL 022529 NDA Eisai Inc. 62856-529 62856-529-60 60 TABLET in 1 BOTTLE (62856-529-60)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength10MG
Approval Date:Jun 27, 2012TE:RLD:Yes
Regulatory Exclusivity Expiration:Jun 27, 2017
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:► SubscribePatent Expiration:Apr 10, 2023Product Flag?YSubstance Flag?YDelist Request?
Patented Use:METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
Patent:► SubscribePatent Expiration:Apr 10, 2023Product Flag?YSubstance Flag?YDelist Request?
Patented Use:METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
McKinsey
Baxter
Harvard Business School
UBS
Medtronic
AstraZeneca
Cantor Fitzgerald
US Department of Justice
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot